Articles published in this journal have questioned the value of sentinel-node biopsy (SNB) for the management of clinically localized primary melanoma. 1, 2 We discuss data that support routine SNB, an approach now widely adopted worldwide. SNB is a minimally invasive staging procedure of low morbidity performed at the same time as wide excision; the first (sentinel) melanomadraining lymph node(s) is identified for focused pathologic study. 3 One in five patients with intermediate-thickness primary melanoma has metastases in regional nodes. These small tumor foci are seldom detectable by clinical or radiologic examination. Before SNB there were two management alternatives, neither of which was satisfactory. Elective, immediate, complete lymph-node dissection (CLND) exposed all patients to morbidity but could only benefit the 20% of patients with nodal metastases. Nodal observation after wide excision avoided unnecessary CLND (i.e. for patients without nodal metastases) but committed all patients to possible delayed CLND if nodal micrometastases became clinically detectable, sometimes 8-10 years later. As sentinel-node tumor status predicts nodal basin status, only patients with sentinel-node metastases need therapeutic immediate CLND; patients with tumor-negative sentinel nodes require no further nodal surgery, have prolonged survival 4 and require fewer follow-up visits.
Articles published in this journal have questioned the value of sentinel-node biopsy (SNB) for the management of clinically localized primary melanoma. 1, 2 We discuss data that support routine SNB, an approach now widely adopted worldwide. SNB is a minimally invasive staging procedure of low morbidity performed at the same time as wide excision; the first (sentinel) melanomadraining lymph node(s) is identified for focused pathologic study. 3 One in five patients with intermediate-thickness primary melanoma has metastases in regional nodes. These small tumor foci are seldom detectable by clinical or radiologic examination. Before SNB there were two management alternatives, neither of which was satisfactory. Elective, immediate, complete lymph-node dissection (CLND) exposed all patients to morbidity but could only benefit the 20% of patients with nodal metastases. Nodal observation after wide excision avoided unnecessary CLND (i.e. for patients without nodal metastases) but committed all patients to possible delayed CLND if nodal micrometastases became clinically detectable, sometimes 8-10 years later. As sentinel-node tumor status predicts nodal basin status, only patients with sentinel-node metastases need therapeutic immediate CLND; patients with tumor-negative sentinel nodes require no further nodal surgery, have prolonged survival 4 and require fewer follow-up visits.
The first Multicenter Selective Lymphadenectomy Trial (MSLT-I) included a primary study group of 1,347 patients with intermediate-thickness (1.2-3.5 mm) melanomas who were randomly allocated to either wide excision plus postoperative observation, with delayed CLND for clinically detectable nodal recurrence; or wide excision plus SNB, with immediate CLND for sentinel-node metastases. Of these patients, 1,269 were evaluable because they accepted assigned treatment. 4 An additional 654 patients with lesions thinner than 1.2 mm (low risk of nodal metastases) or thicker than 3.5 mm (high risk of distant metastases at initial diagnosis) were enrolled to evaluate surgical morbidity and accuracy of the 3, 4 but these patients were considered unlikely to exhibit treatment-related differences in survival according to models developed from the John Wayne Cancer Institute data.
In 2006, the MSLT-I data safety and monitoring board reviewed the third interim analysis and recommended publication of findings with potential significance for management decisions. Although SNB did not improve overall survival, it reduced the relative risk of recurrence at any site by 26% (hazard ratio [HR] 0.74, P = 0.009). 4 Overall, there were fewer local, regional and distant recurrences in the SNB group (20.7% versus 26.8%). 4 Among patients with nodal metastases in the MSLT-I trial, the mean number of tumorinvolved nodes was 1.4 and 3.3 for the SNB and observation groups, respectively (P = 0.001). 4 The observation period, therefore, allows extension of metastases within the nodal basin, 4 which correlates with increased risk of death. 6 MSLT-I demonstrated 5-year survival rates of 72.3 ± 4.6% versus 52.4 ± 5.9% when nodal metastases were managed by SNB and immediate CLND versus observation and delayed CLND (HR for death 0.51, P = 0.004). 4 Among subgroups of all patients who had nodal metastases but comparable prognostic factors, 4 the corresponding survival rates were 66.2% versus 52.4% (HR 0.60, 95% CI 0.40-0.95, P = 0.02) after inclusion of patients who underwent delayed CLND for false-negative SNB results, a group whose survival approximated that of patients who underwent delayed CLND after observation. By comparison, 5-year survival rates for patients without nodal metastases were 93% and 92% in the SNB and observation arms, respectively, confirming the favorable prognostic significance of tumor-negative sentinel nodes. 4 Thomas claims a sentinel-node false-positive rate of 3.8% in MSLT-I, on the basis of the difference between a 19.4% rate of nodal metastasis in the SNB group (16% positive plus 3.4% falsenegative SNBs) and a 15.6% rate of clinical recurrence during nodal observation. 1 This comparison is inappropriate. Most SNB metastases were
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detected by SNB at wide excision, whereas metastases in the observation group occurred during follow-up (median 48.4 months). As followup lengthens, nodal relapses increase, from 78 at the third interim analysis 4 to 84 in the latest report. 5, 7 Thomas' calculation does not consider the 10% of patients who dropped out or were lost to follow-up 4 and, therefore, cannot be assessed for nodal metastasis. The correct calculation requires Kaplan-Meier methodology, which adjusts for censored patients: the actuarial rates of nodal metastases in the SNB and observation arms, respectively, were 19.4% versus 18.5% at 8 years 4 and 20.8% versus 20.5% at 10 years. 4, 7 The equivalent incidence of occult metastases in these groups of patients, well-matched for other prognostic features, 4 indicates that virtually all unresected sentinel-node metastases eventually become detectable. 8 It is not customary to expect survival benefits from a staging procedure, but Thomas 1 and Rosenberg 2 discount SNB because the third interim analysis of MSLT-I showed no significant overall survival benefit. Survival benefits from SNB were limited to the 16% of patients with sentinel-node micrometastases because immediate CLND is performed only for sentinel-node metastases. Any overall survival benefit was, therefore, probably obscured by the 84% of patients whose sentinel nodes were truly or falsely tumor-negative and who only underwent a staging SNB. 4 Overall disease-free survival was significantly better in patients assigned to SNB than to observation (72.5% versus 64.2% at 10 years, P = 0.005). The possibility of recurrence is a great anxiety for patients, 4 and recurrence is an accepted end point for FDA approval of new cancer drugs. 7, 9 Surgical morbidity such as chronic lymphedema is substantially higher after delayed CLND for clinically evident nodal disease. 3, 5, 10 Thomas 1 asserts that sentinel-node metastases not identified by preoperative ultrasonography are prognostically insignificant. He advocates nodal surgery only when ultrasonographic surveillance identifies metastases. Investigators from the Sydney Melanoma Unit and other teams report that ultrasonography rarely detects metastases smaller than 4-5 mm in diameter; 11 64% of sentinel-node metastases in MSLT-I were less than 4 mm and 88% were less than 5 mm. 5, 12 Metastases smaller than 4-5 mm are associated with favorable survival relative to larger metastases, but even tiny micrometastases progress if unresected. 12, 13 In MSLT-II, routine preoperative ultrasonography in 893 patients identified only 8 of 193 (4.2%) patients with sentinel-node micrometastases. 5 Therfore, ultrasonography, as presently practiced, cannot replace SNB for management of intermediate-thickness melanomas.
Most patients with intermediate-thickness melanoma select SNB from the possible nodal management options. SNB is a low-risk, minimally morbid operative procedure that yields accurate staging and prognostic information for treatment planning. Few patients choose longterm nodal observation, with its attendant anxiety and uncertain outcome. MSLT-I data indicate that immediate CLND improves overall disease-free survival of patients with intermediate-thickness melanoma and improves disease-specific survival of the patients with nodal metastases. SNB is a highly accurate technique that correctly stages the regional nodes in at least 96.6% of patients, 4 causes minimal morbidity, and well deserves its current status as the gold standard for staging clinically localized, intermediate-thickness melanoma. 8, 9 
